Actively Recruiting
Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis
Led by Showa Inan General Hospital · Updated on 2025-12-11
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.
CONDITIONS
Official Title
Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with active ulcerative colitis
You will not qualify if you...
- Presence of acute or chronic renal failure
- Presence of chronic heart disease
- Presence of pulmonary infection
- Presence of liver cirrhosis
- Presence of colorectal cancer
- Presence of autoimmune disease
- Presence of infectious disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Showa Inan General Hospital
Komagane, Nagano, Japan, 399-4117
Actively Recruiting
Research Team
N
Norio Saegusa
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here